Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN

Wealthfront Advisers LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 7,006 shares of the biopharmaceutical company's stock, valued at approximately $4,369,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $1,012,296,000. Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company's stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the period. Nuveen LLC increased its holdings in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock worth $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $472,950,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ:REGN opened at $826.64 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $844.92. The company's 50 day moving average is $692.65 and its two-hundred day moving average is $715.90. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company has a market cap of $85.11 billion, a PE ratio of 20.43, a P/E/G ratio of 1.43 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company's revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.29%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent research reports. Piper Sandler reduced their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research report on Thursday, July 9th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. Weiss Ratings reiterated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a "hold" rating in a report on Wednesday, July 29th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $801.70.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes abnormal bone formation. Approval was supported by Phase 3 OPTIMA data showing a 90% or greater reduction in new heterotopic-ossification lesions at 56 weeks, along with fewer clinician-assessed flare-ups. Pasatru is described as the first and only FDA-approved treatment demonstrating these benefits, adding a specialized rare-disease product to Regeneron’s commercial portfolio. Reuters FDA approval article
• Positive Sentiment: The approval creates a potential new revenue stream and strengthens Regeneron’s focus on high-complexity immunology and rare diseases. However, FOP’s very small patient population limits the drug’s absolute market opportunity, while competition from Ipsen could affect adoption and sales. BioPharma Dive Pasatru article
• Neutral Sentiment: Regeneron also reported an update to its Phase 2 study of olatorepatide, signaling continued efforts to enter the obesity-treatment market. The trial remains mid-stage, so any commercial benefit is still several steps away and dependent on future efficacy and safety results. TipRanks olatorepatide article
• Neutral Sentiment: Leerink Partners raised its price target to $824, indicating limited near-term upside relative to the trading level and suggesting the FDA approval may already be substantially reflected in the valuation. Leerink Partners price-target article
• Negative Sentiment: Multiple law firms publicized a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to disclosures surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol amendment and concerns that previously positive messaging did not adequately reflect statistical and trial risks. The notices are largely duplicative, but they reinforce legal, reputational and pipeline uncertainty for REGN. Regeneron securities class-action notice

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the sale, the director owned 603 shares of the company's stock, valued at approximately $482,400. This represents a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 over the last 90 days. Corporate insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source